Werewolf Therapeutics Q4 2024 GAAP EPS $(0.46) Misses $(0.42) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $111M, Expected To Provide Cash Runway Into Q2 Of 2026
Benzinga
2025/03/11
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 39.39 percent decrease over losses of $(0.33) per share from the same period last year.